Abstract
This review describes recent developments in the chemistry of both first and second generation 99m-technetium-based imaging agents. The material is presented according to the biological target for the agent, and where possible actual images are presented to indicate the type of information available to the clinician. Beta emitting isotopes of rhenium offer a possible method for the in situ treatment of cancerous tissue using analogous targeting strategies to those for technetium. Recent developments in the relevant coordination chemistry of rhenium and their extension to in vitro and in vivo studies are presented.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
